OncoConnect Journal Club: Navigating the treatment pathway in sALCL
Prescribing information is available at the top of the page.
Listen to Dr Matthew Wilson describe the treatment pathway in sALCL to gain valuable insights that can be translated into your own clinical practice.
Dr Wilson presents key efficacy and safety data from the ECHELON-2 study,1 which investigated the use of ADCETRIS® + CHP as a treatment option for previously untreated adult patients with sALCL. Dr Wilson also shares his experience using ADCETRIS through real-world case studies.
CHP, cyclophosphamide, doxorubicin and prednisone; sALCL, systemic anaplastic large cell lymphoma. 1. Horwitz S et al. Lancet 2019;393:229–40.
To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.
